Neurocrine Biosciences (NASDAQ:NBIX) Given New $185.00 Price Target at Needham & Company LLC

Neurocrine Biosciences (NASDAQ:NBIX) had its price objective dropped by Needham & Company LLC from $187.00 to $185.00 in a report released on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of 34.60% from the stock’s previous close.

NBIX has been the topic of several other research reports. Citigroup boosted their price objective on Neurocrine Biosciences from $175.00 to $203.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. TD Cowen raised their price objective on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, December 5th. Zacks Research lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 29th. Truist Financial dropped their target price on shares of Neurocrine Biosciences from $172.00 to $169.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Finally, Wall Street Zen upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Fifteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $175.72.

Neurocrine Biosciences Stock Down 0.2%

Neurocrine Biosciences stock opened at $137.44 on Thursday. Neurocrine Biosciences has a 52 week low of $84.23 and a 52 week high of $160.18. The company’s 50 day moving average price is $141.39 and its two-hundred day moving average price is $140.58. The stock has a market cap of $13.70 billion, a P/E ratio of 32.88, a P/E/G ratio of 0.65 and a beta of 0.31.

Insider Buying and Selling at Neurocrine Biosciences

In related news, Director George J. Morrow sold 15,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $143.37, for a total value of $2,150,550.00. Following the completion of the transaction, the director directly owned 7,068 shares in the company, valued at approximately $1,013,339.16. The trade was a 67.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Darin Lippoldt sold 4,376 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $159.65, for a total transaction of $698,628.40. Following the sale, the insider directly owned 43,405 shares in the company, valued at $6,929,608.25. The trade was a 9.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 61,966 shares of company stock worth $8,625,166 over the last three months. Company insiders own 4.80% of the company’s stock.

Institutional Trading of Neurocrine Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in NBIX. AlTi Global Inc. increased its holdings in shares of Neurocrine Biosciences by 1.0% in the 3rd quarter. AlTi Global Inc. now owns 6,828 shares of the company’s stock worth $959,000 after buying an additional 70 shares during the last quarter. Huntington National Bank lifted its stake in Neurocrine Biosciences by 12.6% during the fourth quarter. Huntington National Bank now owns 678 shares of the company’s stock worth $96,000 after purchasing an additional 76 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Neurocrine Biosciences by 0.7% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 11,112 shares of the company’s stock worth $1,560,000 after purchasing an additional 77 shares in the last quarter. Perigon Wealth Management LLC increased its position in shares of Neurocrine Biosciences by 3.1% during the 4th quarter. Perigon Wealth Management LLC now owns 2,590 shares of the company’s stock valued at $367,000 after purchasing an additional 78 shares during the last quarter. Finally, Motley Fool Asset Management LLC raised its holdings in shares of Neurocrine Biosciences by 4.8% during the 4th quarter. Motley Fool Asset Management LLC now owns 1,693 shares of the company’s stock valued at $240,000 after buying an additional 78 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences News Summary

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Management highlighted strong sales growth and durable commercial momentum (INGREZZA) in the Q4 presentation, supporting longer‑term franchise confidence. Neurocrine Biosciences Inc (NBIX) Q4 2025 Earnings Call Highlights: Strong Sales Growth and …
• Positive Sentiment: Analysts remain constructive: Needham kept a Buy and nudged its price target to $185, citing durable Ingrezza growth and an emerging Crenessity ramp despite near‑term cost pressure. Neurocrine Biosciences: Durable Ingrezza Growth and Emerging Crenessity Ramp Support Buy Rating Despite Near-Term Cost Pressures
• Positive Sentiment: TD Cowen and other buyside/agency analysts reiterated Buy ratings, underscoring confidence in franchise momentum and pipeline investments. Neurocrine Biosciences: Durable Franchise Momentum and Pipeline Investment Support Buy Rating
• Neutral Sentiment: The company posted its full PR with product sales and 2026 expectations; Ingrezza full‑year 2026 net product sales guidance was set at $2.7–$2.8 billion (management framed 2026 as a year of investment). Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
• Neutral Sentiment: Full earnings‑call transcript is available for details on pipeline progress, cost items and management commentary that traders will parse for 2026 cadence. Neurocrine Biosciences, Inc. (NBIX) Q4 2025 Earnings Call Transcript
• Negative Sentiment: EPS missed consensus: reported $1.88 vs. street estimates near $2.25–$2.36 (different sources); the bottom‑line shortfall is the main catalyst for the near‑term share weakness. Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates
• Negative Sentiment: Market reaction: shares dipped after the print; coverage pieces note the stock fall and flag extensive insider selling activity in recent months — a potential sentiment headwind. Neurocrine Biosciences Inc. (NBIX) Stock Falls on Q4 2025 Earnings
• Negative Sentiment: Some outlets characterize the company’s 2026 guidance as cautious, reflecting investments and cost pressure that could compress near‑term margins. Neurocrine Biosciences beats Q4 expectations, offers cautious 2026 guidance

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.